Nuvalent, Inc. Nuvalent, Inc.

Nuvalent, Inc.

NUVL

Classifica tra le azioni #2094
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Prezzo delle azioni
$123.96
Ultima sincronizzazione: 2026-07-21
Capitalizzazione di mercato
$9.75B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
36.40%
Paese
US
Scambia Nuvalent, Inc. (NUVL)

Categoria

Healthcare
Storico del prezzo dell'azione per Nuvalent, Inc. (NUVL)
Prezzo di chiusura più alto: $123.86 il 2026-07-01

Prezzo di chiusura più basso: $18.50 il 2021-07-01
Storico del prezzo dell'azione di Nuvalent, Inc. dal 2021 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 0.78%
2025 19.50%
2024 20.56%
2023 136.75%
2022 51.32%
2021 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$527.18 23.62%
US
$251.29 835.90%
US
$137.83 -3.78%
AU
$890.85 9.42%
NL
$755.78 7.42%
CH